Project Grant R37AI184117
Award Date
8/7/24
Completion Date
6/30/29
Dollars Obligated
$844K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
The federal Project Grant award R21AI186928, titled "RIFAPENTINE IN HIGH DOSES IN PREGNANCY WITH TB (RADIANT-MOMS) STUDY", is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $166,541 award will be used by the Trustees of Columbia University in the City of New York to conduct research on optimizing tuberculosis (TB) treatment for pregnant and breastfeeding people, a population...
This $1,350,312 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports the development of a rapid, phenotypic drug susceptibility testing (DST) system for tuberculosis (TB). The primary goal is to design and optimize a novel, trehalose-based DST (TRE-DST) that can accurately diagnose TB drug resistance, including for first- and second-line TB drugs. This includes developing and...
This $766,877 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will fund a pragmatic, randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring in preventing premature discontinuation of the antibiotic linezolid for the treatment of rifampin-resistant tuberculosis. The study, to be conducted by the Albert Einstein College of Medicine, aims to determine if...
This $817,405 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop new 3-4 drug regimens for the treatment of drug-sensitive and drug-resistant tuberculosis (TB). The primary goals are to (1) manufacture and characterize dry powder formulations of the spectinamide compound LEE-1810 for inhalation delivery, (2) determine the optimal dose and dosing frequency of the BPAS...
The $193,316 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on the relationship between HIV exposure, contact networks, and tuberculosis (TB) in children under 5 years old. The award was made on August 20, 2024 to the Boston Medical Center Corporation, a major academic medical center, and will run through July 31, 2029. A sub-award of this grant was made to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $817,252 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center (VUMC) to conduct a study entitled "Investigating Multiple PK and PD Relationships for TB-HIV (IMPPROVE TB-HIV)". This 1-year project aims to leverage VUMC's Tuberculosis Sentinel Research Network to perform pharmacokinetic-pharmacodynamic (PK-PD) analyses on first-line...
This federal Project Grant award of $1,185,782.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform global tuberculosis (TB) research by accelerating the study of human TB lung tissue. The primary goals are to provide two key services to the TB research community: (1) performing pathological, cellular, structural, and/or genetic analysis of resected human TB or postmortem...
This Project Grant award, valued at $1,314,701.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to address gaps in optimizing dolutegravir-based antiretroviral therapy (ART) for children and adolescents. The primary awardee, the University of Florida, will lead the overall research effort, which involves collaborating with sub-awardees Kwame Nkrumah University of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,208,700 to the University of California, San Diego (UCSD) to develop a prototype assay for detecting active tuberculosis (TB) disease in people living with HIV. The key products and services to be delivered through this 2-year project include: Determining the analytical performance of the prototype assay by...
This federal Project Grant award of $787,171, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of new antituberculosis (TB) compounds based on 1,2,4-triazole and pyrrolidine scaffolds. The primary awardee, Washington University in St. Louis, aims to demonstrate preclinical proof-of-concept for these compounds, optimize lead candidates for pharmacological properties, and...